<DOC>
	<DOCNO>NCT00006825</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy monoclonal antibody therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness liposomal doxorubicin trastuzumab treat woman advance breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Trastuzumab Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity , include cardiac toxicity , doxorubicin HCl liposome trastuzumab ( Herceptin ) woman advance HER-2/neu-overexpressing breast cancer . - Determine efficacy regimen patient . OUTLINE : Patients receive doxorubicin HCl liposome IV 1 hour day 1 , follow trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven breast cancer Metastatic disease OR Locoregional relapse follow optimal adjuvant therapy regional treatment HER2/neu overexpression ( 3+ immunohistochemistry OR gene amplification FISH ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : SGOT SGPT great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN unless document arise bone Bilirubin great 1.5 time ULN Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Cardiovascular : LVEF normal radioisotope method No history congestive cardiac failure , myocardial infarction , cardiac arrhythmia , ischemic heart disease require medication Other : Not pregnant nursing Fertile patient must use effective contraception No known sensitivity benzyl alcohol No prior malignancy except adequately treat nonmelanomatous skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : Not specify Chemotherapy : No prior doxorubicin great 240 mg/m2 Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy leave breast chest wall allow Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>